International Journal For Multidisciplinary Research
E-ISSN: 2582-2160
•
Impact Factor: 9.24
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal
Home
Research Paper
Submit Research Paper
Publication Guidelines
Publication Charges
Upload Documents
Track Status / Pay Fees / Download Publication Certi.
Editors & Reviewers
View All
Join as a Reviewer
Get Membership Certificate
Current Issue
Publication Archive
Conference
Publishing Conf. with IJFMR
Upcoming Conference(s) ↓
Conferences Published ↓
ISC-AISGF-TBRF
DePaul-2026
IC-AIRCM-T3-2026
NSSFIGTMA-2025
SPHERE-2025
AIMAR-2025
SVGASCA-2025
ICRTET-4
ICCE-2025
Chinai-2023
PIPRDA-2023
ICMRS'23
Contact Us
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 8 Issue 5
September-October 2026
Indexing Partners
Beyond Standard Protocols: Real-world Challenges and Innovative Solutions in Pediatric Leukemia Management - “Experience from a Tertiary Oncology Center Integrating MRD-guided Therapy and Novel Agents”
| Author(s) | Dr. Shweta Pathak, Dr. Chesta Jain, Dr. Vidya Kumari Saurav, Dr.Monica Lazarus, Dr. Kavya, Dr. Palash, Dr. Lalita Singh |
|---|---|
| Country | India |
| Abstract | Background: Pediatric acute leukemias represent a heterogeneous group of malignancies with variable prognoses. Although survival rates have improved significantly with risk-adapted protocols and advances in supportive care, management becomes complicated in the presence of comorbidity, age-related challenges, or rare molecular subtypes. Objective: To present three pediatric cases—infantile AML, ALL in a child with Down syndrome, and APML with differentiation syndrome—demonstrating diagnostic dilemmas, therapeutic challenges, and the potential of modified regimens. Methods: Retrospective descriptive case series at a tertiary pediatric oncology unit, examining clinical profiles, treatment adaptations, and outcomes. Results: All patients achieved remission. Two required significant modifications due to toxicity or preexisting conditions. Integration of MRD-guided strategies, novel therapeutic agents like azacitidine and venetoclax, and aggressive management of complications led to favorable outcomes. Conclusion: Personalized protocols, vigilant monitoring, and early recognition of complications are essential in pediatric leukemia care. Incorporation of newer agents may rescue patients where traditional therapies fail or are poorly tolerated. |
| Keywords | Pediatric Leukemia, Personalized Therapy, Novel Agents |
| Field | Medical / Pharmacy |
| Published In | Volume 7, Issue 3, May-June 2025 |
| Published On | 2025-06-19 |
| DOI | https://doi.org/10.36948/ijfmr.2025.v07i03.48493 |
Share this

E-ISSN 2582-2160
CrossRef DOI prefix of IJFMR is 10.36948/ijfmr
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.
Powered by Sky Research Publication and Journals